FindTrial
Sign In

Larotrectinib Sulfate

DRUG5 trials

Sponsors

National Cancer Institute (NCI), Children's Oncology Group, M.D. Anderson Cancer Center

Conditions

Advanced LymphomaAdvanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin LymphomaBladder CarcinomaBreast CarcinomaCentral Nervous System NeoplasmCervical Carcinoma

Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Active, not recruitingNCT02465060
National Cancer Institute (NCI)Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma +49
Start: 2015-08-17End: 2026-12-31Target: 6452Updated: 2026-04-03
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
Active, not recruitingNCT03155620
National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma +42
Start: 2017-07-31End: 2027-01-06Updated: 2026-02-10
Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)
Active, not recruitingNCT03213704
National Cancer Institute (NCI)Advanced Malignant Solid Neoplasm, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor +30
Start: 2017-08-23End: 2026-10-08Updated: 2025-12-03
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
Active, not recruitingNCT03834961
Children's Oncology GroupCentral Nervous System Neoplasm, Infantile Fibrosarcoma, Recurrent Acute Leukemia +2
Start: 2019-10-25End: 2027-07-25Updated: 2025-12-02
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
RecruitingNCT04879121
M.D. Anderson Cancer CenterLocally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Start: 2021-04-30End: 2027-11-11Target: 13Updated: 2025-10-30

Related Papers

Phase II Study of Vismodegib in Patients With <i>SMO-</i> or <i>PTCH1</i>-Mutated Tumors: Results From the National Cancer Institute Molecular Analysis for Therapy Choice Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Trial (EAY131) Subprotocol T.
2025-10-09
Comprehensive genomic profiling of matched ctDNA and tissue from patients with less common cancers enrolled in but not eligible for a treatment arm of the NCI-MATCH trial.
Journal of Clinical Oncology2025-05-281 citations
Molecular profiling of plasma from matched NCI-MATCH gynecological cancers.
Journal of Clinical Oncology2024-06-011 citations
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist2024-05-306 citations
Abstract B007: Concordance between tumor tissue and plasma genotyping in NCI-MATCH Trial (EAY131)
Molecular Cancer Therapeutics2023-12-01
Revolutionizing cancer drug development: Harnessing the potential of basket trials.
2023-11-0720 citations
The NCI-MATCH trial: lessons for precision oncology.
2023-06-15103 citations
Phase 2 study of larotrectinib in children with newly diagnosed infantile fibrosarcoma (IFS): Children’s Oncology Group (COG) ADVL1823 cohort A.
Journal of Clinical Oncology2023-06-015 citations
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.
Journal of Clinical Oncology2023-06-013 citations
Phase II study of crizotinib in patients with <i>MET</i> amplification and <i>MET</i> exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.
Journal of Clinical Oncology2023-06-012 citations
Discovery of gene fusions in driver-negative NCI-MATCH screening samples.
Journal of Clinical Oncology2023-06-011 citations
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
Nature Medicine2023-04-14244 citations
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Clinical Cancer Research2023-01-2055 citations
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
npj Precision Oncology2022-10-2715 citations
Abstract 2438: Determining the role of non-mutated C-Raf kinase in metastatic disease
Cancer Research2022-06-15
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
2022-06-077 citations
Phase II study of vismodegib in patients with <i>SM</i>O or <i>PTCH1</i> mutated tumors: Results from NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol T.
Journal of Clinical Oncology2022-06-013 citations
Molecular predictors of response among patients with MMRd tumors treated on NCI-MATCH Arm Z1D.
Journal of Clinical Oncology2022-06-01
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers
The Oncologist2022-04-1445 citations
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies
Cancer Discovery2022-03-16143 citations

25 more papers not shown